Hypertension and dyslipidemia are important risk factors for cardiovascular disease.
However, the clinical outcomes of fixed‐dose combination (FDC) versus free‐equivalent …

Background Hypertension and hypercholesterolemia are important risk factors for
cardiovascular disease, and treatment with fixed‐dose combination (FDC) regimens is …

Background Blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) are
important risk factors for cardiovascular (CV) diseases. Although treating these factors …

Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …

Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …

Background: According to epidemiological data, patients with both hypertension (HTN) and
dyslipidemia (DYS) often fail to achieve goals for both conditions, despite their increased …

Background Few data are available regarding the efficacy and safety of a single-pill
combination (SPC) consisting of four medications in patients with concomitant hypertension …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple
combination of amlodipine/losartan/rosuvastatin in patients with hypertension and …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …